Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 7,101–7,200 of 15,747
Iriyama, C., Ichikawa, T., Tamura, T., Takahata, M., Ishio, T., Ibata, M., Kawai, R., Iwata, M., Suzuki, M., Adachi, H., et al. (2025) · PNAS Nexus · doi:10.1093/pnasnexus/pgaf085 · Cited by 11
“…of COVID-19 has gradually improved with the use of monoclonal antibody therapeutics sotrovimab (6), casirivimab/imdevimab (7), and tixagevimab/cilgavimab (8); antiviral drugs remdesivir (9), molnu-piravir (10), and ritonavir-boosted nirmatrelvir (11); and anti-SARS-CoV-2 mRNA vaccines (12, 13).”
Therapeutic peptides and proteins: Status and developments in drug delivery
Hornsby, B. D., Lee, C. H., Steele, C. A., Tuekpe, J. K. K., & Lim, C. S. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114895 · Cited by 25
Morphology evolution of lipid nanoparticle discovered by small angle neutron scattering
Li, Y., Ma, C., Han, Z., Weng, W., Yang, S., He, Z., Li, Z., Su, X., Zuo, T., & Cheng, H. (2024) · Giant · doi:10.1016/j.giant.2024.100329 · Cited by 14
Delvino, P., Bartoletti, A., Cassaniti, I., et al. (2021) · Lara D. Veeken · doi:10.1093/rheumatology/keab776 · Cited by 10
Nonhuman primate models for evaluation of SARS-CoV-2 vaccines
Neil, J. A., Griffith, M., Godfrey, D. I., Purcell, D. F. J., Deliyannis, G., Jackson, D. C., Rockman, S., Subbarao, K., & Nolan, T. M. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2071264 · Cited by 12
“were observed in older vaccinees) and resulted in 95% efficacy against COVID-19 disease [52].”
BackgroundTedeschi, S. K., Solomon, D. H., Chen, Y., Ellrodt, J., Whelan, M. G., Stratton, J., Hayashi, K., Whiteman, N. B., Chen, L., Adejoorin, I., et al. (2023) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2023.152177 · Cited by 9
“Two mRNA COVID-19 vaccines (mRNA-1273, manufactured by Moderna and BNT162b2, manufactured by Pfizer) demonstrated excellent efficacy against severe COVID-19 among healthy adults in two large randomized controlled trials (RCTs) [3,4].”
Meyers, E., Deschepper, E., Duysburgh, E., Rop, L. D., Burghgraeve, T. D., Ngoc, P. V., Digregorio, M., Delogne, S., Coen, A., Clercq, N. D., et al. (2022) · Viruses · doi:10.3390/v14112361 · Cited by 12
“Moreover, these trials only assessed the immune responses upon vaccination among persons under 85 years of age [3,4], while the average age of an NHR in Belgium is 87 years of age [5].”
BackgroundTran, V. P., Tran, T. T., Hao, H. T., Hau, N. T. H., Jain, N., & Reinis, A. (2023) · Human Antibodies · doi:10.3233/hab-220013 · Cited by 10
Waning effectiveness of mRNA COVID-19 vaccines against inpatient and emergency department encounters
Giannouchos, T. V., Hair, N. L., Olatosi, B., & Li, X. (2024) · PLoS ONE · doi:10.1371/journal.pone.0300198 · Cited by 12
The advent of automated medicine? The values and meanings of precision
Prainsack, B. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780198863465.003.0015 · Cited by 17
Wimalawansa, S. J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e34691 · Cited by 12
“In the Moderna randomized controlled trial (RCT), serious adverse effects (SAEs) occurred at a rate of 15.1 per 10,000 participants, compared to 6.4 per 10,000 participants in the placebo group — a 2.4-fold higher risk of SAEs than the reduction observed in COVID-19 hospitalization [190].”
BackgroundResultInfluentialRetinal venous occlusion in a child following Corbevax COVID-19 vaccination
Nangia, P., Prakash, V. J., & Majumder, P. D. (2022) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_1927_22 · Cited by 10
(2021) · doi:10.1101/2021.07.15.21260595 · Cited by 76
Nasr, S., Khalil, S. D. S., Poiesz, B. J., et al. (2021) · Clinical Immunology Communications · doi:10.1016/j.clicom.2021.08.001 · Cited by 10
Experience of danaparoid to treat vaccine-induced immune thrombocytopenia and thrombosis, VITT
Myllylahti, L., Pitkänen, H. H., Magnani, H., & Lassila, R. (2022) · Thrombosis Journal · doi:10.1186/s12959-021-00362-y · Cited by 10
Efficient Isolation of Bacterial RNAs Using Silica-Based Materials Modified with Ionic Liquids
Pereira, P., Pedro, A. Q., Neves, M. C., Martins, J. C., Rodrigues, I., Freire, M. G., & de Sousa, F. P. (2021) · Life · doi:10.3390/life11101090 · Cited by 11
“Currently, RNA is regarded as an important drug target and the RNA-based biopharmaceuticals market is expected to assume more relevance in the future, a tendency that seems to start being confirmed due to the worldwide distribution of messenger RNA for tackling the COVID-19 pandemics [3].”
BackgroundGiustina, A., Marazuela, M., Reincke, M., Yıldız, B. O., & Puig‐Domingo, M. (2021) · European Journal of Endocrinology · doi:10.1530/eje-21-0397 · Cited by 10
Natural killer cells in adoptive cell therapy: current landscape of genetic engineering strategies
Burón, M., Etxebarria, A., Álvarez, M., Romayor, I., & Eguizábal, C. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2563099 · Cited by 11
“Specifically, Pfizer-BioNTech´ 128 and Moderna´s 129–131 vaccines have demonstrated the excellent efficacy of lipid nanoparticles (LNPs) as delivery vectors for COVID-19 mRNA.”
Zhang, B., Fong, Y., Dang, L., Fintzi, J., Chen, S., Wang, J., Rouphael, N., Branche, A. R., Diemert, D. J., Falsey, A. R., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-55931-w · Cited by 16
Yamaguchi, Y., Nameki, S., Kato, Y., Saita, R., Sato, T., Nagao, S., Murakami, T., Yoshimine, Y., Amiya, S., Morita, T., et al. (2022) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2022.100661 · Cited by 10
Chhatwal, J., Xiao, J., Mueller, P. P., Adee, M. G., Dalgic, O. O., Ladd, M. A., Ayer, T., & Linas, B. P. (2021) · medRxiv · doi:10.1101/2021.08.11.21261845 · Cited by 10
Facciuolo, A., Scruten, E., Lipsit, S., Lang, A. L. S., Cates, Z. P., Lew, J. M., Falzarano, D., Gerdts, V., KUSALIK, A. J., & Napper, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-12032-8 · Cited by 9
Sourij, C., Aziz, F., Kojzar, H., Obermayer, A. M., Sternad, C., Müller, A., Tripolt, N. J., Pferschy, P. N., Aberer, F., Schlenke, P., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14855 · Cited by 9
Lockmer, S., Uttervall, K., Kashif, M., Svärd, C., Malmsten, K., Fletcher‐Torres, E., Alici, E., Lund, J., & Nahi, H. (2021) · American Journal of Hematology · doi:10.1002/ajh.26348 · Cited by 12
“The COVID-19 mRNA vaccine BNT162b2 produced by PfizerBioNTech is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine, encoding the membrane-anchored SARS-CoV-2 fulllength spike protein, stabilized in a prefusion conformation.(3) It was first authorized for active immunization in December 2020.”
BackgroundMatsumoto, N., Hagiya, H., Nakayama, M., Furukawa, M., Mitsuhashi, T., Takao, S., Otsuka, F., & Yorifuji, T. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.09.012 · Cited by 9
“In response, several vaccines have been developed to limit the severity of the pandemic [2],[3],[4].”
Hu, L., Zhang, S., Sienkiewicz, J., Zhou, H., Berahovich, R., Sun, J., Li, M., Ocampo, A., Liu, X., Huang, Y., et al. (2024) · Vaccines · doi:10.3390/vaccines12070808 · Cited by 15
“LNPs have been shown to be a safe, reliable, and efficient mRNA delivery platform that addresses these challenges effectively since its application in the two widely used COVID-19 mRNA vaccines mRNA-1273 [79] and BNT162b [80].”
BackgroundTo Use Face Masks or Not After COVID-19 Vaccination? An Impact Analysis Using Mathematical Modeling
Kinyili, M., Munyakazi, J. B., & Mukhtar, A. Y. A. (2022) · Frontiers in Applied Mathematics and Statistics · doi:10.3389/fams.2022.872284 · Cited by 10
Vaccination against SARS-CoV-2 in Patients with Inflammatory Bowel Diseases: Where Do We Stand?
Tepasse, P., Vollenberg, R., & Nowacki, T. M. (2021) · Life · doi:10.3390/life11111220 · Cited by 10
“In phase III trials, both vaccines showed an efficiency above 94% in preventing COVID-19 in the study population, accompanying a good safety profile [15,16].”
BackgroundInfection with SARS-CoV-2 primes immunological memory in human nasal-associated lymphoid tissue
Mahallawi, W. H., & Aljeraisi, T. M. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108850 · Cited by 11
Roth, N., Gergen, J., Kovacikova, K., Mueller, S. O., Ulrich, L., Schön, J., Halwe, N. J., Fricke, C., Corleis, B., Dorhoi, A., et al. (2023) · Vaccines · doi:10.3390/vaccines11020318 · Cited by 10
“BNT162b2 (Comirnaty, Pfizer/BioNTech) and mRNA-1273 (Spikevax, Moderna) monovalent mRNA COVID-19 vaccines, approved in December 2020 and April 2021 respectively, were generally well tolerated and highly effective at reducing the severity of COVID-19 symptoms caused by the ancestral strain [14,15].”
BackgroundCortés-Sarabia, K., Gutiérrez-Torres, M., Mendoza-Renteria, E. M., Leyva‐Vázquez, M. A., Vences-Velázquez, A., Hernández‐Sotelo, D., Beltrán‐Anaya, F. O., Moral-Hernández, Ó. D., & Illades‐Aguiar, B. (2022) · Vaccines · doi:10.3390/vaccines10060909 · Cited by 14
“The serology has been used for the evaluation of COVID-19 vaccines, considering the recombinant RBD derived from SARSCoV-2 as the main antigen.”
InfluentialTransgene Delivery to Human Induced Pluripotent Stem Cells Using Nanoparticles
Yamoah, M., Thai, P. N., & Zhang, X.-D. (2021) · Pharmaceuticals · doi:10.3390/ph14040334 · Cited by 13
Effects of BNT162b2 mRNA Covid-19 vaccine on vascular function
Yamaji, T., Harada, T., Hashimoto, Y., Nakano, Y., Kajikawa, M., Yoshimura, K., Goto, C., Han, Y., Mizobuchi, A., Yusoff, F. M., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302512 · Cited by 13
Th2-Oriented Immune Serum After SARS-CoV-2 Vaccination Does Not Enhance Infection In Vitro
Luan, N., Li, T., Wang, Y., Cao, H., Yin, X., Lin, K., & Liu, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.882856 · Cited by 10
SARS-CoV-2 re-infection risk in Austria
(2021) · doi:10.1101/2021.02.08.21251362 · Cited by 10
The design and analysis of vaccine trials for COVID ‐19 for the purpose of estimating efficacy
Senn, S. J. (2022) · Pharmaceutical Statistics · doi:10.1002/pst.2226 · Cited by 12
An assessment of the vaccination of school-aged children in England against SARS-CoV-2
Keeling, M. J., & Moore, S. (2022) · BMC Medicine · doi:10.1186/s12916-022-02379-0 · Cited by 12
(2021) · doi:10.21203/rs.3.rs-355257/v1 · Cited by 10
“Available mRNA COVID19 vaccines have been approved due to their capacity to reduce symptomatic disease, hospitalizations, and deaths in clinical trials [2,3]; evidence of their real-world effectiveness is growing [4–6], but confirmation still remains limited to certain populations and settings [7–9].”
BackgroundResultCosta, C. S., Scozzari, G., Migliore, E., Galassi, C., Ciccone, G., Ricciardelli, G., Scarmozzino, A., Angelone, L., Cassoni, P., Cavallo, R., et al. (2022) · Vaccines · doi:10.3390/vaccines10071031 · Cited by 13
“The BNT162b2 vaccine (Comirnaty®, Pfizer/BioNTech, Mainz, Germany) is a lipid nanoparticle–formulated, nucleoside-modified RNA (modRNA) encoding the SARS-CoV2 full-length spike glycoprotein, with an efficacy in preventing COVID-19 approaching 95% [1].”
BackgroundCase report of acute myocarditis after administration of coronavirus disease 2019 vaccine in Japan
Ohnishi, M., Tanaka, Y., Nishida, S., & Sugimoto, T. (2022) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytab534 · Cited by 11
Lessons for medical countermeasure development from unforeseen outbreaks
Mura, M., Trignol, A., Dault, E. L., & Tournier, J. (2025) · Emerging Microbes & Infections · doi:10.1080/22221751.2025.2471035 · Cited by 10
“…viral vector vaccines, protein subunit vaccines, and inactivated virus vaccines each offering unique strengths and facing distinct challenges (Table 2). mRNA vaccines have demonstrated exceptional efficacy, with clinical trials reporting up to 95% protection against symptomatic COVID-19 [72,73].”
Flowers, R. C., Rodriguez, B. R., & Corbitt, K. (2021) · BMJ Case Reports · doi:10.1136/bcr-2021-243066 · Cited by 10
Heesen, G., Heinemann, S., Müller, F., Dopfer‐Jablonka, A., Mikuteit, M., Niewolik, J., Klawonn, F., Vahldiek, K., Hummers, E., & Schröder, D. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1080106 · Cited by 12
Piros, É. A., Cseprekál, O., Görög, A., et al. (2022) · Dermatologic Therapy · doi:10.1111/dth.15408 · Cited by 10
Posterior ocular manifestations following BNT162b2 mRNA COVID-19 vaccine: a case series
Pillar, S., Weinberg, T., & Amer, R. (2022) · International Ophthalmology · doi:10.1007/s10792-022-02565-2 · Cited by 10
“BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein [1].”
BackgroundBruminhent, J., Setthaudom, C., Phornkittikorn, P., Chaumdee, P., Prasongtanakij, S., Srisala, S., Malathum, K., Boongird, S., Nongnuch, A., Assanatham, M., et al. (2022) · American Journal of Transplantation · doi:10.1111/ajt.17151 · Cited by 10
O’Donnell, C. W., Farelli, J. D., Belaghzal, H., Chen, J., Beech, L., Sullivan, J. M., Morrison-Smith, C. D., Siecinski, S. K., Katz, A., Mildrum, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57920-5 · Cited by 16
Yang, X., Zhang, J., Liu, Z., Chen, S., Olatosi, B., Poland, G. A., Weissman, S., & Li, X. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.11.029 · Cited by 13
“The remarkable efficacy of COVID-19 vaccines was observed in both large, randomized-controlled US clinical trials and real-world settings [1,2], where four vaccines were found to be safe and efficacious in preventing symptomatic COVID-19.”
BackgroundTransient inhibition of lysosomal functions potentiates nucleic acid vaccines
Wang, C., Karlsson, A., Oguin, T. H., Macintyre, A. N., Sempowski, G. D., McCarthy, K. R., Wang, Y., Moody, M. A., & Yuan, F. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2306465120 · Cited by 10
Austin, L. A., Smith, J. S., Nahas, D. D., Danzinger, A., Secore, S., O’Donnell, G. T., Radcliffe, S., Hu, S., Perley, J., Bett, A. J., et al. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00635 · Cited by 10
Spiera, E., Ganjian, D. Y., Zhang, X., Brenner, E. J., Agrawal, M., Colombel, J., Kappelman, M. D., Kornbluth, A. A., & Ungaro, R. C. (2022) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izab337 · Cited by 9
Chhetri, B., Vamsi, D. K. K., Prakash, D. B., Balasubramanian, S., & Sanjeevi, C. B. (2022) · Computational and Mathematical Biophysics · doi:10.1515/cmb-2022-0143 · Cited by 10
Hayashi, H., Sun, J., Yanagida, Y., Otera, T., Sasai, M., Chang, C. Y., Tai, J. A., Nishikawa, T., Yamashita, K., Sakaguchi, N., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-24519-5 · Cited by 12
Bellitto, C., Luxi, N., Ciccimarra, F., L’Abbate, L., Raethke, M., van Hunsel, F. P. A. M., Lieber, T., Mulder, E., Riefolo, F., Villalobos, F., et al. (2024) · Drug Safety · doi:10.1007/s40264-024-01449-x · Cited by 10
“…information on solicited local (injection site haematoma, induration, inflammation, pain, pruritus, swelling, and warmth) and systemic ADRs (arthralgia, chills, fatigue, headache, malaise, myalgia, nausea, and fever), based on the most frequently reported adverse events in pivotal trials [14–16].”
BackgroundKuzmina, A., Wattad, S., Engel, S., Rosenberg, E., & Taube, R. (2022) · Viruses · doi:10.3390/v14040803 · Cited by 11
“These vaccines exhibit high efficiency in preventing viral infection and disease progression [10,13,21,64].”
BackgroundEvidence base for yearly respiratory virus vaccines: Current status and proposed improved strategies
Barosa, M., Ioannidis, J. P. A., & Prasad, V. K. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14286 · Cited by 12
“71 Nevertheless, to the best of our knowledge, results have never been published.”
Development of DNA Vaccine Candidate against SARS-CoV-2
Wang, X., Rcheulishvili, N., Cai, J., Liu, C., Xie, F., Hu, X., Yang, N., Hou, M., Papukashvili, D., He, Y., et al. (2022) · Viruses · doi:10.3390/v14051049 · Cited by 13
Tsilibary, E.-P. C., Charonis, S. A., & Georgopoulos, A. P. (2021) · Vaccines · doi:10.3390/vaccines9010047 · Cited by 9
Retrospective analysis of equity-based optimization for COVID-19 vaccine allocation
Stafford, E., Dimitrov, D., Ceballos, R. M., Campelia, G. D., & Matrajt, L. (2023) · PNAS Nexus · doi:10.1093/pnasnexus/pgad283 · Cited by 12
Cui, H., Xu, Y., Pang, K., Li, G., Gong, F., Wang, B., & Li, B. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.14.638383 · Cited by 10
Beyond Traditional Medicine: EVs-Loaded Hydrogels as a Game Changer in Disease Therapeutics
Du, S., Zhou, X., & Zheng, B. (2024) · Gels · doi:10.3390/gels10030162 · Cited by 11
“The safety and conversion efficiency of mRNA through chemical modification in vitro synthesis were demonstrated in the widespread use of mRNA as a vaccine in the 2019 Novel Coronavirus Disease (COVID-19) pandemic [87,88].”
MethodAmini, A., Garner, L. C., Shaw, R. H., Kelly, N. E. W., Adele, S., Skelly, D., Dejnirattisai, W., Greenland, M., Liu, X., Heslington, A., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.adu3337 · Cited by 16
Walmsley, S. L., Nabipoor, M., Qi, F., Lovblom, L. E., Ravindran, R., Colwill, K., Dayam, R. M., Tursun, T. R., Silva, A., Gingras, A., et al. (2024) · Vaccines · doi:10.3390/vaccines12060564 · Cited by 11
“Despite the dramatic effectiveness of COVID-19 vaccines in preventing severe illness, hospitalization, and death due to COVID-19 infection [1,2], breakthrough infections are common, with 50–80% of most populations having acquired natural infection [3–7] after immunization.”
BackgroundVarelas, C., Gavriilaki, E., Sakellari, I., Klonizakis, P., Koravou, E., Christodoulou, I., Mavrikou, I., Kourelis, A., Chatzopoulou, F. M., Chatzidimitriou, D., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11040937 · Cited by 10
“These questions extend further to patients suffering from hematologic diseases, including adult SCD patients, due to their impaired immunity and to the limited information available on whether and to what extent they could mount functional immune responses, as these patients were generally excluded from vaccination tr…”
BackgroundChang, C. T., Lim, X.-J., Chew, C.-C., Philip, R., Chan, H., Hassan, M. R. A., Shafie, A. A., & Lee, S. W. H. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.10.057 · Cited by 10
“The safety and efficacy of mRNA COVID-19 vaccines was reported in December 2020 [2], followed by a systematic review in 2021 [9].”
BackgroundPascucci, D., Nurchis, M. C., Sapienza, M., Castrini, F., Beccia, F., D’Ambrosio, F., Grossi, A., Castagna, C., Pezzullo, A. M., Zega, M., et al. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182111098 · Cited by 10
“The 95% credible interval for vaccine effectiveness was calculated adopting a Bayesian beta-binomial model [8].”
BackgroundMethodPapadopoulos, D., Ntanasis‐Stathopoulos, I., Gavriatopoulou, M., Evangelakou, Z., Malandrakis, P., Manola, M. S., Gianniou, D. D., Kastritis, E., Trougakos, I. P., Dimopoulos, M. A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10020204 · Cited by 9
Sung, J., Liu, Y., Wu, K.-C., Choi, M.-C., Ma, C., Lin, J., He, E., Leung, D., Sze, E. T.-P., Hamied, Y. K., et al. (2021) · Vaccines · doi:10.3390/vaccines10010002 · Cited by 11
“The safety of COVID-19 vaccines is under scrutiny [35,36].”
BackgroundRetractedInfluence of Seasonality and Public-Health Interventions on the COVID-19 Pandemic in Northern Europe
Quinn, G. A., Connolly, M., Fenton, N., Hatfill, S. J., Hynds, P. D., ÓhAiseadha, C. O., Sikora, K., Soon, W., & Connolly, R. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020334 · Cited by 13
“These were widely seen as being very effective at reducing the incidence of symptomatic COVID-19 [5–9].”
BackgroundResultInfluentialColucci, M., Santis, E. D., Totti, B., Miroballo, M., Tamiro, F., Rossi, G., Piepoli, A., Vincentis, G. D., Greco, A., Mangia, A., et al. (2021) · Vaccines · doi:10.3390/vaccines9101207 · Cited by 11
“Despite not being designed to assess the efficacy of a single-dose regimen, a divergence between placebo and vaccine recipients starts at 12 days after the first dose, an indication of an early onset of a partially protective immunization, with an efficacy of 52% in the interval between the first and second dose [3,12…”
BackgroundFusco, R., Simonetti, I., Ianniello, S., Villanacci, A., Grassi, F., Dell’Aversana, F., Grassi, R., Cozzi, D., Bicci, E., Palumbo, P., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12040624 · Cited by 11
Zhuo, R., Charlton, C. L., Plitt, S. S., Thompson, L. A., Braun, S., Day, J., Osiowy, C., Tipples, G. A., & Kanji, J. N. (2022) · Journal of Clinical Virology · doi:10.1016/j.jcv.2022.105292 · Cited by 13
Mild Symptomatic SARS-CoV-2 P.1 (B.1.1.28) Infection in a Fully Vaccinated 83-Year-Old Man
Fabiani, M., Margiotti, K., Viola, A., Mesoraca, A., & Giorlandino, C. (2021) · Pathogens · doi:10.3390/pathogens10050614 · Cited by 11
“1 oc‐ curring in an individual in Italy after the second dose of the Pfizer BNT162b2 mRNA COVID‐19 vaccine [5].”
BackgroundKhan, U. I., Hassan, I., Niaz, M., Azam, S. I., Hasan, Z., Mahmood, S. F., & Ali, A. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-071789 · Cited by 8
Uptake of COVID-19 booster shot among healthcare workers: A mediation analysis approach
Rehman, S., Rehman, E., & Jianglin, Z. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1033473 · Cited by 11
Mata, E., Broset, E., Matute, C., Stoian, A. M., Adame, S., Alejo, T., López, A., Andrés, B., Heredero, J., de Miguel, D., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01201-1 · Cited by 13
Developing microbiology literacy in biology education college: future teacher candidates
Fidiastuti, H. R., Lestari, S. R., Suhadi, S., & Prabaningtyas, S. (2024) · Journal of Microbiology and Biology Education · doi:10.1128/jmbe.00035-24 · Cited by 20
“…as an aseptic working principle, (ii) use of masks and face shields to prevent virus transmission (48), (iii) maintaining distance, avoiding crowds, and limiting mobility as a form of preventing viral spread (49, 50), (iv) body immunity to virus exposure (51) and vaccination developments (52, 53).”
BackgroundIn-silico screening of naturally derived phytochemicals against SARS-CoV Main protease
Mostafa, I., Mohamed, N. H., Mohamed, B., Almeer, R., Abulmeaty, M. M. A., BUNGAU, S. G., El-Shazly, A. M., & Yahya, G. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-17642-9 · Cited by 13
The COVID-19 pandemic reveals the wide-ranging role of biobanks
Juozapaitė, D., Minkauskas, M., Laurinaitytė, I., Simutytė, M., Griškevičius, L., & Naumovas, D. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1256601 · Cited by 12
“The COVID-19-related mortality in immunocompromised patients is significantly higher compared to the healthy population (30, 31) and the vaccine effectiveness in these patients was unclear, as they have not been included in the clinical trials (32, 33).”
BackgroundCovid-19 third vaccination during pregnancy: maternal and neonatal outcomes—a retrospective study
Rottenstreich, M., Rotem, R., Weil‐Weiner, Y., Grisaru‐Granovsky, S., & Sela, H. Y. (2022) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-022-06786-9 · Cited by 11
“The safety of the vaccine as mentioned above in terms of obstetrical complications along with the safety of the vaccine in the general population [10] and later as evident in the obstetric population [22] and the reduced risk of SARSCoV-2 infection in pregnant women [23] all may have a led to the increase in the uptak…”
BackgroundResultLetter to the Editor: Financial incentives for COVID-19 vaccination
Kim, H. B. (2021) · Epidemiology and Health · doi:10.4178/epih.e2021088 · Cited by 10
Herpetic Eye Disease After SARS-CoV-2 Vaccination: A CDC-VAERS Database Analysis
Singh, R. B., Parmar, U. P. S., Ichhpujani, P., Jeng, B. H., & Jhanji, V. (2023) · Cornea · doi:10.1097/ico.0000000000003246 · Cited by 10
Vaccine Design: An Introduction
Fiyouzi, T., & Reche, P. A. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3239-0_1 · Cited by 12
Toniutto, P., Aghemo, A., Grossi, P., Burra, P., Carrai, P., Donato, M. F., Giannelli, V., Martini, S., Morelli, M. C., & Ponziani, F. R. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.07.019 · Cited by 11
Bariatric surgery and COVID-19 outcomes: a systematic review and meta-analysis
Cai, Z., Zhong, J., Jiang, Y., & Zhang, J. (2023) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2023.02.023 · Cited by 10
“COVID-19 caused by SARSCoV-2 can be divided into mild, moderate, severe, and critical categories based on clinical characteristics, and imaging and laboratory parameters [13].”
BackgroundCheng, Y., Zhao, E., Yang, X., Luo, C., Zi, G., Wang, R., Xu, Y., & Peng, B. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.125024 · Cited by 15
Comunicación visual de una emergencia sanitaria mundial: el caso de la Covid-19
Pérez–Montoro, M. (2021) · Anuario ThinkEPI · doi:10.3145/thinkepi.2021.e15d01 · Cited by 10
Effect of COVID vaccination on monthly migraine days: a longitudinal cohort study
van der Arend, B. W. H., Bloemhof, M. M., van der Schoor, A. G., van Zwet, E. W., & Terwindt, G. M. (2023) · Cephalalgia · doi:10.1177/03331024231198792 · Cited by 11
Torres, M. J., Labella, M., María, R. S. D. S., Bogas, G., Salas, M. L., Fernández, T. D., Mayorga, C., & Doña, I. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612829666221024154951 · Cited by 12
Vacunación contra SARS-CoV-2 y su relación con enfermedad y muerte por COVID-19 en Argentina
Scruzzi, G. F., Aballay, L. R., Carreño, P., Rousseau, G. A. D., Franchini, C. G., Cecchetto, E., Willington, A. P., Barbás, M. G., & López, L. (2022) · Revista Panamericana de Salud Pública · doi:10.26633/rpsp.2022.39 · Cited by 19
“39 significativas por edad, sexo y comorbilidades, ni entre grupos poblacionales (4).”
BackgroundYoshimura, Y., Sasaki, H., Miyata, N., Miyazaki, K., Okudela, K., Tateishi, Y., Hayashi, H., Kawana‐Tachikawa, A., Iwashita, H., Maeda, K., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.04.057 · Cited by 10
Hamilton, E. M., Oversby, S., Ratsch, A., & Kitchener, S. J. (2022) · Vaccines · doi:10.3390/vaccines10050657 · Cited by 9
“Despite the ChAdOx1-S vaccine being a highly effective and safe vaccine [21], the extremely rare side effect of thrombosis with thrombocytopenia syndrome (TTS) was subject to considerable controversy and negative media coverage over the Australian vaccine rollout, having a damaging impact on people’s intention to be v…”
BackgroundCOVID-19 in Africa: an ovarian victory?
Dufailu, O. A., Afriyie-Asante, A., Gyan, B., Adu, D. K., Yeboah, H., Ntiakoh, F., & Asare-Werehene, M. (2021) · Journal of Ovarian Research · doi:10.1186/s13048-021-00820-1 · Cited by 12
“to protecting people from SARS-CoV-2 infection [11, 12].”
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.